Media inquiries: media@celsiustx.com
Investor inquiries: investor@celsiustx.com
March 24
First Clinical Candidate, Anti-TREM1 Antibody for IBD, Identified Through Novel SCOPE Platform; Phase 1 Study Anticipated in Early 2023 $83 Million in Additional Financing CAMBRIDGE, Mass. – March 24, 2022 – Celsius Therapeutics, a biotechnology company leveraging its human tissue-based platform to develop precision medicines for patients with cancer and autoimmune disease, today provided a […]
December 21
PARIS, France and CAMBRIDGE, Mass., US – December 21st, 2020 – Servier, a global pharmaceutical Group, and Celsius Therapeutics, a company focused on bringing precision medicine to patients with cancer and autoimmunity, today announced a strategic collaboration focused on the identification and validation of novel colorectal cancer (CRC) drug targets. “As colorectal cancer remains a leading contributor […]
July 1
CAMBRIDGE, Mass., July 1, 2020 – Celsius Therapeutics, a company focused on bringing precision medicine to patients with autoimmunity, cancer and other complex diseases, today announced the signing of three collaboration agreements with the University of Oxford (Oxford, UK), Cleveland Clinic (Cleveland, U.S.) and the LMU University Hospital Munich (Munich, Germany). In each agreement, Celsius […]
May 12
Cambridge, MA – May 12, 2020 – Celsius Therapeutics, a company focused on bringing precision medicine to patients with cancer, autoimmunity and other complex diseases, today announced the appointment of Jeanne Magram, Ph.D., to chief scientific officer. Christoph Lengauer, Ph.D., a partner at Third Rock Ventures and co-founder and former interim chief scientific officer of […]
September 23
Cambridge, MA – September 23, 2019 – Celsius Therapeutics, a company focused on bringing personalized medicine to patients with cancer, autoimmunity and other complex diseases, today announced that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the […]
September 19
Celsius Applying its Single-Cell Genomics Platform Across Multiple Tumor Types and Immuno-Oncology Clinical Trials CAMBRIDGE, Mass., September 19, 2019 – Celsius Therapeutics, a company focused on bringing personalized medicine to patients with cancer, autoimmunity and other complex diseases, today announced the signing of collaboration agreements with the Parker Institute for Cancer Immunotherapy (San Francisco, USA), Institut […]
July 9
Celsius to Apply its Single-Cell Genomics and Machine Learning Platform at Unprecedented Scale in Large Phase 2 Clinical Study CAMBRIDGE, Mass., July 9, 2019 – Celsius Therapeutics, a company focused on the discovery and development of precision therapeutics for patients with autoimmune diseases and cancer, today announced a collaboration with Janssen Biotech, Inc. Under the terms […]
June 11
Experienced biopharma leader brings business development, strategy and company-building expertise to accelerate Celsius’ growth
May 22
Greg Ryslik, Ph.D., Appointed to Chief Data Officer
Michael Boretti, Ph.D., Appointed to Chief Business Officer
May 15
Company Created to Understand the Cellular Ecosystem of Disease Through Single-Cell Genomics
Media inquiries: media@celsiustx.com
Investor inquiries: investor@celsiustx.com
Cell. 2019 Dec 12;179(7):1609-1622.e16. doi: 10.1016/j.cell.2019.11.010.
Cell. 2019 Nov 14;179(5):1160-1176.e24. doi: 10.1016/j.cell.2019.10.027.
Cell. 2019 Sep 5;178(6):1493-1508.e20. doi: 10.1016/j.cell.2019.08.008. Epub 2019 Aug 29.
Cell. 2019 Jul 25;178(3):714-730.e22. doi: 10.1016/j.cell.2019.06.029.
Nature. 2019 Mar;567(7746):49-55. doi: 10.1038/s41586-019-0992-y. Epub 2019 Feb 27.
Cell. 2019 Jan 10;176(1-2):404. doi: 10.1016/j.cell.2018.12.034. No abstract available.
Cell. 2018 Dec 27;176(4):775-789.e18. doi: 10.1016/j.cell.2018.11.043
BioRxiv. 2018 Nov 12. doi: 10.1101/461228
Cell. 2018 Nov 1;175(4):984-997.e24. doi: 10.1016/j.cell.2018.09.006.
Cell. 2018 Nov 1;175(4):1031-1044.e18. doi: 10.1016/j.cell.2018.09.009. Epub 2018 Oct 11.
Nature. 2018 Oct 29; 564:268–272
Nature Communications. 2018 Feb 23; 9(789)
Nature. 2017; 541(7637):331-338.
Science. 2017;358(6359):58-63.
Nature. 2017;547(7662):173-178.
Science. 2017;356(6335):pii:eaah4573.
Science. 2017; 355(6332):eaai8478.
Cell. 2017;171(7):1611-1624.e24.
Science. 2016;353(6302):925-928.
Science. 2016;352(6282):189-196.
You are now leaving Celsius Therapeutics to visit a third-party website, which is solely responsible for all content and privacy policies.